2023
DOI: 10.1021/acs.oprd.3c00287
|View full text |Cite
|
Sign up to set email alerts
|

Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline

Juliana M. S. Robey,
Sanjay Maity,
Sarah L. Aleshire
et al.

Abstract: Bedaquiline (BDQ) is an important drug for treating multidrug-resistant tuberculosis (MDR-TB), a worldwide disease that causes more than 1.6 million deaths yearly. The current synthetic strategy adopted by the manufacturers to assemble this molecule relies on a nucleophilic addition reaction of a quinoline fragment to a ketone, but it suffers from low conversion and no stereoselectivity, which subsequently increases the cost of manufacturing BDQ. The Medicines for All Institute (M4ALL) has developed a new reac… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 45 publications
(36 reference statements)
0
1
0
Order By: Relevance
“…As an additional complication, a lack of treatment options can give rise to multidrug-resistant TB strains (MDR-TB) . After a decades-long drought of new TB treatments, several new drugs have been developed in recent years, including bedaquiline, , linezolid, pretomanid, and delamanid, and combination regimens of these drugs such as BPaL. , However, ensuring low costs for these new treatment options remains a top priority for the global health community.…”
Section: Introductionmentioning
confidence: 99%
“…As an additional complication, a lack of treatment options can give rise to multidrug-resistant TB strains (MDR-TB) . After a decades-long drought of new TB treatments, several new drugs have been developed in recent years, including bedaquiline, , linezolid, pretomanid, and delamanid, and combination regimens of these drugs such as BPaL. , However, ensuring low costs for these new treatment options remains a top priority for the global health community.…”
Section: Introductionmentioning
confidence: 99%